RESUMO
Nasolacrimal duct injury is a well established complication of functional endoscopic sinus surgery. In 1992, Bolger reported an incidence of nasolacrimal duct injuries in endoscopic sinus surgery of up to 15 per cent, but there is no documentation in microscopic sinus surgery. Fluorescein instillation into the lacrimal system via the punctum was done to determine the incidence of nasolacrimal duct injuries in 16 patients who underwent 32 microscopic sinus procedures. Only one patient exhibited nasolacrimal duct injury intraoperatively on the left side (0.3%). He had complete healing of the nasolacrimal duct at 2 months and no postoperative epiphora developed.
Assuntos
Microcirurgia/efeitos adversos , Pólipos Nasais/cirurgia , Ducto Nasolacrimal/lesões , Sinusite/cirurgia , Adolescente , Adulto , Idoso , Meios de Contraste , Feminino , Fluoresceína , Humanos , Masculino , Pessoa de Meia-Idade , Ducto Nasolacrimal/fisiopatologiaRESUMO
An open-label, non-comparative study was performed in three Otolaryngology centers in Bangkok, Thailand, to assess the efficacy, safety and tolerability of fexofenadine in Thai patients with perennial allergic rhinitis. Altogether 101 perennial allergic rhinitis patients were included, 33 males and 68 females. Mean age was 33 years, average duration of symptoms was 6 years. All patients received fexofenadine hydrochloride 120 mg once daily (OD) in the morning for 2 weeks. Patients recorded their allergy symptoms daily using a 5 point rating scales in the diary card. At the end of 2 weeks, patients and investigators assessed the overall efficacy of treatment. Adverse events and onset of symptom relief were also recorded by every patient. Blood test and ECG were performed before and after treatment in one center (Siriraj Hospital). Total symptom scores and nasal scores decreased significantly from a baseline at 1 week and 2 weeks after treatment (p < 0.05). The mean onset of symptom relief was 2 hours and 12 minutes. The global assessment of the treatment by patients and investigators showed significant concordance. There was no significant change in either the vital signs, laboratory tests or ECG. The incidence of treatment related adverse events was 8% but all were mild and easily tolerated. Drowsiness was reported from only one patient. This study suggests that fexofenadine 120 mg once daily was an effective, safe and well tolerated treatment for perennial allergic rhinitis in Thai patients.
Assuntos
Antialérgicos/uso terapêutico , Antagonistas dos Receptores Histamínicos H1/uso terapêutico , Rinite Alérgica Perene/tratamento farmacológico , Terfenadina/análogos & derivados , Terfenadina/uso terapêutico , Adolescente , Adulto , Idoso , Antialérgicos/administração & dosagem , Antialérgicos/efeitos adversos , Esquema de Medicação , Eletrocardiografia , Feminino , Antagonistas dos Receptores Histamínicos H1/administração & dosagem , Antagonistas dos Receptores Histamínicos H1/efeitos adversos , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Multicêntricos como Assunto , Terfenadina/administração & dosagem , Terfenadina/efeitos adversos , Tailândia , Fatores de TempoRESUMO
.3 per cent ofloxacin solution has been studied widely and has been proved to be safe in both animal and human studies. Ototoxicity and hair cell damage were not found in animal experiments. Ototopical treatment in both pediatric and adult patients was proved to be safe in previous studies. P. aeruginosa and S. aureus play the major role in both CSOM and OE, and most causative pathogens are susceptible to ofloxacin. This study showed that the use of 0.3 per cent ofloxacin otic solution was safe in both children and adults and yielded excellent clinical results.
